Combined Therapy with Bioacoustic Correction and Pharmacotherapy in Panic and Generalized Anxiety Disorders: A Randomized Controlled Trial

The study is dedicated to evaluating the effectiveness of bioacoustic correction (BAC) in combination with first-line pharmacotherapy for the treatment of patients with panic disorder (PD) and generalized anxiety disorder (GAD). A randomized controlled trial involved 60 patients divided into two groups: the main group (30 individuals) received first-line pharmacotherapy for PD and GAD along with 15 sessions of BAC, while the control group (30 individuals) received only pharmacotherapy. Assessment was conducted using the HARS (anxiety), MADRS (depression), GAD-7, and the SF-36 quality of life questionnaire. The results showed that the main group demonstrated a significant reduction in scores on anxiety scales (HARS: 45.5%) and depression scales (MADRS: 68.9%) compared to the control group (p < 0.05). Quality of life improved in both groups, but the main group showed more pronounced progress in psychological aspects (social functioning, vitality). After 4 weeks of observation, the stability of the effect was higher in the main group (CGI: 2 vs. 3 points in the control). Intergroup differences in physical indicators of the SF-36 were found to be insignificant, indicating a predominant effect of BAC on affective symptoms. The combination of BAC with pharmacotherapy enhances anxiolytic and antidepressant effects, contributing to sustained remission. This method may be recommended for patients with PD, GAD, as well as comorbid anxiety and depressive disorders, especially when standard treatment is insufficiently effective.